Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 1interventionalRules rewrite

Phase 1: testing Atezolizumab for Locally Advanced Alveolar Soft Part Sarcoma

Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow.

Official registry: https://clinicaltrials.gov/study/NCT06066138 · National Cancer Institute (NCI) · enrollment listed as 30

What this phase means

Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Atezolizumab. The registry lists allocation as na. Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment.

They plan to enroll about 30 people at Bethesda. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Interventions: Atezolizumab

Primary outcome (registry wording): Feasibility of reducing drug exposure while maintaining plasma drug concentration

Who it is for (from inclusion criteria)

  • Ages 18 Years to 120 Years
  • Age \>=18 years old
  • Measurable disease per RECIST 1.1 criteria
  • how well you can do daily activities (ECOG score) of 0-2
  • Participants must have adequate organ and marrow function as defined below:
  • Absolute neutrophil count (ANC) \>=1,200/microliter
  • Hemoglobin \>9.0 g/dL
  • Platelets \>=75,000/microliter

Public study contact (from the registry)

NCI Medical Oncology Referral Office

(240) 760-6050

ncimo_referrals@nih.gov

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Evaluation for NCI Surgery Branch Clinical Research Protocols

Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.

NCT00001823 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

FAQ about this NCT record

Is NCT06066138 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06066138?

Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06066138?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary